Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Second Generation Andexanet Alfa in Healthy Subjects
NCT03083704Phase 1Completed
- Sponsor
- Portola Pharmaceuticals
- Start
- Feb 2017
- Primary completion
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of andexanet alfa in hemorrhage (11 cohorts), sponsored by Portola Pharmaceuticals. Primary endpoints: Pharmacokinetics, Reversal of Anticoagulation and 4 more. Started Feb 2017; status: completed.
02
Drugs
andexanet alfa
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT03083704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083704.